Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

NCT06515418 on ClinicalTrials.gov · last registry update 2025-03-13

Stopped early, having planned 204 participants. The sponsor logged completion for 6 February 2025. Primary outcome, as filed: Mean Percent Change in Body Weight (Azelaprag Once per Day). tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: TERMINATED
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: BioAge Labs, Inc.
Sponsor type: Industry
Enrollment: 204
Started: 2024-06-27
Primary completion: 2025-02-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean Percent Change in Body Weight (Azelaprag Once per Day)

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.